@ARTICLE{Bujko-Wasiak2024:i7926,
	author="{Bujko-Wasiak, Natalia and Jędrzejczak, Wiesław and Brzozowska, Agnieszka and Petrasz, Piotr and Brzeźniakiewicz-Janus, Katarzyna}",
	title="{Succesful CPX-351 treatment of seminoma therapy-related acute myeloid leukemia in a patient with Klinefelter syndrome}",
	year="2024",
	type="artykuł naukowy",
	language="en",
	journal="{Acta Haematologica Polonica}",
	issn="0001-5814",
	volume="55",
	number="3",
	pages="177--179",
	doi="10.5603/ahp.99607",
	url="https://journals.viamedica.pl/acta_haematologica_polonica/article/view/99607",
	keywords="CPX-351; acute myeloid leukemia; therapy-related acute myeloid leukemia",
	abstract="{Therapy-related acute myeloid leukemia (t-AML) is one of the most severe distant complications of cancer treatment. With the prolonged survival of patients cured of neoplasia the issue of distant complications becomes significant. Both, radiation and cytotoxic drugs used in such therapy, are mutagenic and the risk of development of t-AML reaches 1% per year in some studies. Moreover, t-AML is more resistant to treatment than primary leukemia, while patients may be more fragile to adverse effects than subjects not earlier exposed to cytotoxic therapies. Hence, need to use novel and less toxic approaches to their treatment. One of the newly available compounds is CPX-351: liposomal preparation of cytosine arabinoside with daunorubicin. Below we report its successful use in the AML patient with Klinefelter syndrome earlier cured of seminoma.}",
}